Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 1-8 results of 8
Head and Neck Cancer

ALLIANCE / A092105

Official Title: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer 
Study Purpose: To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab
Status: Recruiting
Head and Neck Cancer

ECOG-ACRIN / EA3132

Official Title: Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer
Study Purpose: To compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone.  A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Status: Recruiting
Head and Neck Cancer

ECOG-ACRIN / EA3191

Official Title: Testing What Happens When An Immunotherapy Drug (Pembrolizumab) Is Added To Radiation Or Given By Itself Compared To The Usual Treatment Of Chemotherapy With Radiation After You Have Had Surgery For Your Recurrent Squamous Cell Carcinoma Of The Head And Neck
Study Purpose: To compare usual approach (chemotherapy plus radiation) to pembrolizumab alone and pembrolizumab in combination with radiation after having head and neck cancer surgically removed.
Status: Recruiting
Head and Neck Cancer Other Trials

ECOG-ACRIN / EA3231

Official Title: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
Study Purpose: To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.
Status: Recruiting
Head and Neck Cancer

GSK 221530

Official Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Study Purpose: To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC 
Status: Recruiting
Head and Neck Cancer

NRG / HN006

Official Title: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity CancerRandomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Study Purpose: To see if neck and shoulder function and pain are better after SLN biopsy surgery compared to the usual approach and to see if SLN biopsy surgery is as good as the usual approach in extending your time without cancer.
Status: Suspended
Head and Neck Cancer

NRG / HN010

Official Title: Testing the use of ado-trastuzumab emtansine compared to the usual treatment (chemotherapy with docetaxel plus trastuzumab) for recurrent, metastatic, or unresectable HER2-Positive salivary gland cancer.
Study Purpose: Will ado-trastuzumab emtansine extend the length of time without your cancer getting worse compared to standard of care?
Status: Recruiting
Head and Neck Cancer

NRG / HN011

Official Title: A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Study Purpose: To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.
Status: Recruiting